AVEO Pharmaceuticals (AVEO) seems to be a great long-term investment
What’s up with AVEO Pharmaceuticals?
AVEO Pharmaceuticals (AVEO) opened at $7.86, which means the stock is up 7.10% from yesterday’s closing price of 7.71. Today, the company has a high of $8.45 and a low of $7.68. The company has a market cap of $131.86 million with a 52-week high of $11.20 and a 52-week low of $2.23.
What about the future for AVEO Pharmaceuticals?
The high forecast for AVEO Pharmaceuticals is 18.00 while the low is 10.00. Stock forecasts are based on human experience: Human traders based on their experience in terms of stock price patterns, volume changes, and market news/rumors regarding a particular stock. AVEO Pharmaceuticals has a strong forecast. A strong forecast is a result of strong earning reports as investors are willing to pay a higher share price today because of growth expectations in the future. Based on this information AVEO seems to be a safe buy.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.